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Soluble forms of the interferon-a receptor (sIFN-aR) were identilicd in human serum and urine by Western blotting with monoclonal antibodies 
(MAb) dircctLvl against IFN-aR, and by immunoprccipitation (Iptn) of a covslently cross-linked complex of IFN-aR and [‘Zl]lFN-a with anti 
IFN-a MAb. Elevated levels of slFN-aR were found in sera of hairy ccl1 leukemia patients. Tbc soluble rcccplor from serum migrated as a 55 
kDa protein in SDS-PAGE, and, as expected, the cross-linked product migrated as a 75 kDa protein. The soluble receptor from urine was found 
to be n protein of mol. wt. 45 kD;L and its cross-linked complex migrated as a 65 kDa protein. The cnlculatcd mol. wt. of the entire cxtracellular 
domain of the IFN-aR prior to post-translational modifications is 47,000. Since thcrc are I2 potential glycosylation poinls in this Cltlmalltir 
domain, its actual mol. wt. may be as high as 70,000 Da. It is thurcl’ore concluded that slFN-aR molecules, corresponding to truncated forms of 
the cxtraccllulur dotnain of the cell surkc IFN-aR. arc present in human serum and in normal human urine. 
Cytokinc; Hairy cell leukemia; &rum; Urine 
1. INTRODUCTION 
Interferon (IFN)-a constitutes a family of structur- 
ally related cytokines, defined by their ability to confer 
resistance to viral infections. Many other biological ac- 
tivities of IFN-a have been reported, including inhibi- 
tion of cell proliferation, induction of class I MHC 
antigens and several other immunoregulatory activities 
[l]. IFN-a is useful for the treatment of several viral 
diseases, including hepatitis C [2] and viral warts [3], as 
well as certain malignancies, uch as hairy cell leukemia 
[4], chronic myelogenous leukemia [S] and Kaposi’s sar- 
coma [6]. 
As in the case of other cytokines, IFN-a exerts its 
biological activities by binding to a cell surface receptor, 
which is common to all IFN-a subtypes, as well as 
IFN-P. Human IFN-a receptor was identified and 
cloned from Daudi cells [7]. When expressed in murine 
cells this receptor makes the~n responsive to human 
IFN-aB and, to a lesser extent, to other IF-N-a species, 
indicating that additional receptors or accessory pro- 
teins may be involved in the response to various IFN-a 
subtypes. The cloned receptor had a single transmem- 
brane domain, an extracellular and an intracellular do- 
main. 
Several soluble cytokine receptors which correspond 
to the extracellular ligand binding domains of the rc- 
spective cell-associated receptors were recently identi- 
fied. These include the soluble receptors of IL-6, IFN-y 
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[S-10], TNF [ll], IL-1 [6] and lL-4 [13]. Based on these 
findings we suggested that the previously reported solu- 
ble IL-2 receptor [14] was not a unique case but, rather, 
all cytokine receptors have soluble counterparts in body 
fluids [S]. Here we report that a soluble form of the 
human IFN-a receptor is present in serum and urine. 
2. MATERIALS AND METHODS 
2.1s Rcugcrrts 
Scra of palients WCFC obtained from Dr. Dan Aderka (Ichilov HOS- 
pitnl. Tel-Aviv, Israel). Crude urinary proteins of normal individuals, 
concentrated I .OOO-fold [S], were obtained from Scrono Laboratories, 
Rome, Italy; anti-IFN-a monoclonalantibody (MAb) No. 74.3 immo- 
bilized on agorosc hydrazide (Sigma) was prcparcd as described [IS]; 
di-N-hydroxysuccinimidyl subcratc (DSS) was from Pierce. 
1.2. hnr~titti:utiun of mice, ceff Jirsion attd scrwtting (rrmtociono~ anti- 
bodies to tire IFhktR. nmtuwipt itt prryarutiorr) 
Balblc mice were injected with a partially puriftd preparation of E: 
coh IFN-aR fused to protein A (IOygImousbinjection). The mouse 
showing the highest tiler by invcrtcd sRlA (see below) was chosen rOF 
fusion. Its splenic lymphocytes wcrc fused with an NSO/I myuloma 
variant (NSO cells. kindly providd by C. Milstein. MRC. Cnmbridgc, 
UK). Hybridoma supcrnatants wore tested for chc prcscncc of anli- 
IFN-aR antibodies by an inverted sRIA. Microtitcr plates wcrc 
coated with affinity-purified goat anti-mouse antibodies followed by 
the addition of hybridoma supcmatants and [“‘I]IFN-(rR. Hybrido- 
mas that were found to secrete anti-IFN-aR antibodies wet-c cloned 
and rccloncd by the limiting dilution technique. Supernattmt of hy- 
bridoma No. 21.4 was used in this study. 
2.3. imrrfcrons 
Recombinant IFN-a2 (2 x IO8 Ulmg) was kindly provided by Dr. 
C. Weismann, University of Zurich. IFN-aB (2 x 10’ U/m@ was 
kindly provided by Dr. Gruter from Cibn-Geigy. IFNsB was lab&d 
by a modification of the chloraminc T method 1161. Briefly, 7 fig of 
IFN-aB was labeled with I mCi afNa[1Z51] in the presence of 1 m&ml 
of chlomminr T (20 s 3n ice), to a specific activity of 4 x IO’ cptn&g. 
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2.4. We.dcnt Blotritrg 
Samples were subjected to SDS-PAGE under non-reducing condi- 
tions and ekctroblotted (in 25 mM l’ris. 1.92 mM glycine. 20% mcth- 
anal) onto nitroccllulosc sheets (Schleicher und Schuell, 0.43 /ml). 
Following electroblotting the sheet was incubated with a Blocking 
buffer (10% non-tat milk in PBS containing 0.05% Twecn-20 and 
0.02% sodium uzidc) and then for 2 h at room umpcmture with the 
anti-IFN-aR antibody. The nitrocellulose sheet wus washed with 
0.05% Tween-20 in PBS and incubated overnight at 4OC with [“‘l]goat 
anti-mouse antibodies (0.7 x lo6 cpnziml, in the Blocking buffer). The 
blot wus then washed. dried and autoradioyraphcd. 
Samples of serum or urine were incubated (I h at 4’C) with 
[‘Z51]lFN-aB (300,000 cpm) in the absence or in the presence of a 
IOO-fold ~XCCSS of unlabeled IPN-aB or IFN-a2. DSS dissolved in 
dimethyl sulfoxide (Me$O) was then added to a final concenmlion 
of 1 mM and the mixture was left for 20 min at 4OC. The reaction wus 
stopped by the addition of I M Tris-HCI. pH 7.5, and I M NaCl lo 
a final concentration of 100 mM. The samples were immunoprecipi- 
tated by the addition of anti-IFN-a MAb immobilized on agarose 
hydrazide (25 ~1. 7 m&ml) [l5]. Following incubation (overnight. 
J’C). the beads were washed 3 times with PBS, suspended in a sample 
buffer containing 2% mcrcnptoethanol and the suprrnattunts were 
analysecl by SDS-PAGE (7.5% or 10% acrylamide gels [17]) followed 
by autoradiography, 
3. RESULTS 
Sera from two hairy cell leukemia (HCL) patients and 
normal human sera (NHS) were subjected to SDS- 
PAGE under non-reducing conditions and Western 
blotting with anti-IFN-aR MAb. The HCL serum ex- 
hibited a band of mol. wt. 55 kDa (Fig. 1, lanes C and 
D), while no such band was observed in NHS (Fig. 1, 
lane I3). The high mol. WC. protein seen in lanes B-D was 
most probably serum immunoglobulin which cross-re- 
97 
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acted with the second antibody used in the Western 
blotting. In order to characterize the 55 kDa protein 
and to check its l&and binding ability, aliquots of the 
various set-a were covalently cross linked to [tz51]IFN- 
aB. A specific but weak band of mol. wt. 75 kDa could 
be observed (lanes F). The cross-linked products were 
enriched by Iptn with immobilized anti-IFN-a MAb. 
Indeed a broad band centering around 75 kDa, proba- 
bly consisting of the 55 kDa protein cross-linked to 
[“‘I]IFN-a, was clearly observed in the HCL sera (lanes 
H and J) but not in the NHS (lane L). The specificity 
of this binding was verified by cross-linking experiments 
in the presence of an excess of either unlabelled IFN-a2 
or IFN-aB. Indeed the 75 kDa band was significantly 
reduced (lanes I and K). In addition to the speci8c 
(displacable) 75 kDa band, some non-displacable bands 
(SO, 80, 97 and >lOO kDa) were observed. The non- 
specific 80 kDa band (clearly seen in lanes H-M) could 
not be completely resolved from the 75 kDa band. It 
should be noted that in some experiments traces of 
slFN-aR were detected in NHS by cross-linking and 
Iptn [not shown). 
A sample of crude urinary proteins obtained from 
normal individuals (1 ,ul 1 ,OOO-fold concentrated) was 
subjected to SDS-PAGE under non-reducing condi- 
tions, followed by Western blotting with anti-IFN-aR 
MAb. A protein band of mol. wt. 45 kDa was observed 
(Fig. 2a). The high mol. wt. protein seen in the same 
lane was identified by protein microsequencing as 
human immunoglobulin that cross-reacted with 
[“S1]goat anti-mouse antibodies. The iigand binding ca- 
pacity of the 45 kDa protein was checked by incubating 
a crude urine sample with [‘251]IFN-aB in the presence 
Fig. 1. (a) Western blotting of human scra with anti-IFN-oR MAb. Lanes: A, mol. wt. markers (kDa); B, normal human serum (NM, 5 ~1); C 
and D, surum iron-r a hairy ceii lcrkeu~in (i-iCij pniiant (5 and : ,& rcsp&vcb). (5) Auto.,,. **~Atogra.m of cross-linked complexes. Lanes: E, mol. 
wt. markers (kDa); F, serum (Tkd) from an HCL patient cross-IinkLul to [1Z51]lFN-aB; G, NHS (5,ul)cross-linked to [‘3’l]IFN-a13. (c) Autoradiogram 
of cross-linked complcxcs following Iptn with anti-IFN-a MAb. Lanes: H-K, serum (50,ul) from an HCL patient cross-linked to [1Z51]lFN-aB in
the absence (H and J) or in the presence of an excess of unlabellcd IFN-a2 (I) or IFN-aB (K); L and M, NHS (50,~l) cross-linked to [‘251]lFN-aB 
in the absence (L) or in the presence (M) of unlabclled IFN-a2; N, mol. wt. markers (kDa). 
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Fig. 2. (n) Western blotting or slFN-aR from urine. Lanes: A, mol. 
wt. markers (kDa); 13, cruoe urine (I pl). (b) Auloradiognm of a 
cross-linked comalex of urinnrv slFN-aR and I~~slllFN-a followinn 
!pm. Lanes: C, Lrinnry prot&ns, 1,000~fold cbnc~ntlntcd (100 ~6 
cross-linked to [1251]IFN-aB and immunoprccipituted with anti-lFN-a 
MAb; D, Same as C except hat excess unlnbcled IFN-aB was added 
prior to cross-linking; E:, mol. wt. markers (kDa). 
or absence of excess of unlabeled IFN-a, and then 
cross-linking with DSS. Following lptn with anti-IFN-a 
MAb and SDS-PAGE, a specific cross-linked product 
of mol. wt. 65 kDa was detected (Fig. 2b). This complex 
was smaller by 10 kDa than the cross-linked complex 
from serum. 
In conclusion, two forms ofsIFN-aR were found in 
body fluids, a 55 kDa protein in serum and a 45 kDa 
protein in urine. 
4. DISCUSSION 
sIFN-aR forms were identified in human serum and 
urine with the aid of a newly developed anti-IFN-aR 
MAb. High levels of sIFN-aR were found in sera of 
HCL patients that were undergoing IFN-a therapy, 
whereas the levels in NHS were very low. It is possible 
that IFN-a increases hedding or release of the slFN- 
aR in vivo. We observed that IFN-a treatment of Daudi 
cells in vitro resulted in a significant down-regulation of 
a 90 kDa membrane-bound IFN-aR. Such down-regu- 
lation could stem from shedding of the extracellular 
domain of the receptor. Furthermore, we obtained indi- 
cations that a sIFn-aR of the same size as that of the 
receptor in serum (55 kDa) is present constitutively in 
culture medium of Daudi cells (manuscript in prepara- 
&:-..\ LIVU,. 
The calculated mol. wt. of the entire extracellular 
domain of the IFN-aR prior to post-translationai mod- 
ifications is 47,000 Da. Since there are 12 potential N- 
glycosylation sites in this extracellular domain, its ac- 
tual mol. wt. may be as high as 70,000 Da. Thus it 
appears that the natural@ occurring soluble receptors 
are truncated forms of the extracellular portion of the 
IFN-a receptor. The truncation could occur at either 
rermini of the extracellular portion of the receptor and 
may consist of both a polypeptide and a polysaccharidc. 
Interestingly, the two soluble receptors for human TNF 
were found to be C- and N-terminally truncated [18]. 
The urinary IFN-aR has a mol. wt. which is lower by 
10 kDa than that of the soluble receptor found in serum 
and cell culture medium. This 45 kDa urinary protein 
is probably generated by further truncation of the solu- 
ble 55 kDa receptor. 
Both forms of the slFN-aR retained the ability to 
bind their Ii&and, as demonstrated by cross-linking ex- 
periments which yielded complexes of mol. wt. G5 kDa 
(urine) and 75 kDa (serum). In both cases the mol. wt. 
corresponded to a 1: 1 complex of the respective soluble 
receptor and the 20 kDa IFN-a. An excess of either 
IFN-aB or IFN-a2 added to the cross-linking reactions 
significantly reduced the signal, thereby proving the 
specificity of the interaction between these soluble re- 
ceptors and IFN-a. 
Based on the sensitivity of the Western blotting we 
estimate that the concentration of the soluble receptor 
in normal human urine is in the range of 0.1-l ng/rnI, 
while the level in serum from HCL patients is in Ihe 
range of lo-100 ng/ml. Similar levels (1 nglml for urine, 
20-40 &ml for NHS and 150-250 ndml, in sera of 
HIV-scropositivc patients) were found in the case of the 
soluble IL-G receptor [19,20]. 
The sIFN-aR is a newly discovered member of the 
family of soluble cytokine receptors. So far the physio- 
logical role of the soluble cytokine receptors has not 
been established. Two mechanisms have been proposed 
for the formation of these receptors: (i) proteolytic 
cleavage of the membrane anchored receptor, as shown 
with IL-2R [21] and TNF-RI [22], and (ii) alternative 
splicing of mRNA as in the case of IL-4 [23], IL-6 [24] 
and IL-7 [25]. The soluble receptors bind their specific 
ligands and modulate their activity. In some cases they 
inhibit the biological activity, as was shown in the TNF 
system [26,27], while in some other cases t.*ley enhance 
the activity of the cytokine, as demonstrated with Lhc 
lL-6 system [28]. The recombinant soluble TNF recep- 
tor was found to prevent septic shock in animal models 
[29], and soluble forms of the IL-l receptor were found 
to have profound inhibitory effects on the development 
of in vivo alloreactivity in mouse allagraft recipients 
[30]. Similarly, the soluble forms of IFN-aR may tind 
use as modulators of IFN-a activity in autoimmune 
disease in which aberrant expression of IFN-a was re- 
ported, e.g. systemiF Illpus erythcmatosus 1311. .I...._ .- 
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